<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05092438</url>
  </required_header>
  <id_info>
    <org_study_id>QIAGEN</org_study_id>
    <nct_id>NCT05092438</nct_id>
  </id_info>
  <brief_title>QIAstat-Dx® Meningitis/Encephalitis Panel Performance Evaluation Study</brief_title>
  <official_title>An Observational, Retrospective, Clinical Performance Study Testing Residual Specimens of Cerebrospinal Fluid Obtained by Lumbar Puncture From Meningitis/Encephalitis Subjects Using the QIAstat-Dx® Meningitis/Encephalitis Panel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>QIAGEN Gaithersburg, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>QIAGEN Gaithersburg, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study for performance evaluation of the QIAstat-Dx® Meningitis/Encephalitis Panel in&#xD;
      comparison with other chosen comparator methods.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicenter study aims to evaluate the performance of QIAstat-Dx Meningitis/Encephalitis&#xD;
      (ME) Panel with another validated comparator method.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 8, 2021</start_date>
  <completion_date type="Anticipated">November 18, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 18, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>sensitivity</measure>
    <time_frame>6 weeks</time_frame>
    <description>positive percentage agreement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>specificity</measure>
    <time_frame>6 weeks</time_frame>
    <description>negative percentage agreement</description>
  </primary_outcome>
  <enrollment type="Actual">600</enrollment>
  <condition>Meningitis/Encephalitis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      frozen residual specimens of CSF obtained by lumbar puncture&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects (adults and children) with signs and symptoms of meningitis and/or encephalitis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Residual specimens of CSF obtained by lumbar puncture from subjects with signs and symptoms&#xD;
        of meningitis and/or encephalitis following completion of routine testing Specimen that had&#xD;
        not been centrifuged Adequate residual volume (≥400 μl)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Specimens not fitting criteria outlined above. CSF obtained from an external ventricular&#xD;
        drain or shunt source Lack of clear subject identification or label on residual banked CSF&#xD;
        specimen. Obvious physical damage of banked residual specimen. Repeat specimens from the&#xD;
        same subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Johnson</last_name>
    <role>Study Director</role>
    <affiliation>QIAGEN Gaithersburg, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Qiagen</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>all samples are residual and anonymized</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

